Plasmodium immunotherapy for cancer - CAS Lamvac BiotechAlternative Names: Plasmodium cancer vaccine - CAS Lamvac Biotech
Latest Information Update: 15 Jun 2016
At a glance
- Originator Guangzhou Institutes of Biomedicine and Health
- Developer CAS Lamvac Biotech; State Key Laboratory of Respiratory Disease
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Non-small cell lung cancer
Most Recent Events
- 26 May 2016 Phase-I/II clinical trials in Non-small cell lung cancer in China (Parenteral) (NCT02786589)